AKT1 and prostate carcinoma: Fourthly, mutations in tumour suppressor proteins, such as loss of PTEN which is a common event occurring in about 60% of prostate cancer patients results in the activation of the phosphatidylinositol 3'-kinase (PI3K) signal transduction cascade resulting in increased cellular proliferation and survival mediated by AKT [6].